Advanced search
Publication Cover
Cancer Investigation Volume 30, 2012 - Issue 10
Submit an article Journal homepage
303
Views
33
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Caio M. Rocha LimaDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,Correspondence[email protected]
,
Soley BayraktarDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Aurea M. FloresDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Jessica MacIntyreDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Alberto MonteroDivision of Hematology/Oncology University of Miami, and Sylvester Comprehensive Cancer Center, University of Miami Hospital & Clinics, Miami, Florida, USA,
,
Joaquina C. BarandaDepartment of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA,
,
John WallmarkAssociates in Oncology/Hematology, PC, Rockville, Maryland, USA,
,
Chia PorteraGenentech, Inc., South San Francisco, California, USA
,
Rajiv RajaGenentech, Inc., South San Francisco, California, USA
,
Howard SternGenentech, Inc., South San Francisco, California, USA
,
Stephanie Royer-JooGenentech, Inc., South San Francisco, California, USA
&
Lukas C. AmlerGenentech, Inc., South San Francisco, California, USA
 show all
Pages 727-731 | Published online: 12 Oct 2012
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.